ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development
Dr. Ambler’s presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therapeutic agents and the implications for clinical development.
- Dr. Ambler’s presentation will review the current standards for antimicrobial susceptibility testing (AST) for the determination of antibacterial activity of therapeutic agents and the implications for clinical development.
- She will highlight and discuss various antibiotics in current use and several investigational agents that require a modified AST method, such as the Company’s DLAs.
- Review and approval of new AST methods by standards development organizations, such as the Clinical and Laboratory Standards Institute (CLSI), is essential.
- The Company will be presenting two posters describing the initial development of the exebacase MIC method for testing Staphylococci other than Staphylococcus aureus (SoSA) and method verification studies performed to evaluate test performance.